• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 在尿路上皮膀胱癌中的表达在不同标本类型之间的变化大于在伴随检测之间的变化。

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.

机构信息

Department of Urology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

出版信息

Virchows Arch. 2021 Oct;479(4):705-713. doi: 10.1007/s00428-021-03094-6. Epub 2021 Apr 28.

DOI:10.1007/s00428-021-03094-6
PMID:33909149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8516767/
Abstract

Urothelial bladder cancer (UBC) patients ineligible to platinum-based chemotherapy can be treated with immune-checkpoint inhibitors (ICI) in Programmed Death Ligand 1 (PD-L1) positive cases. Although concordance exists between different PD-L1 assays, little is known on PD-L1 expression variability in matched UBC samples. We compared PD-L1 expression in whole slides of matched transurethral resections (TURBT), radical cystectomies (RC), and lymph node metastasis (LN). Immunohistochemistry using the VENTANA PD-L1 (SP263) assay was performed on 115 patients and scored positive if expression occurred in ≥25% immune cells (IC), ≥25% tumour cells (TC), or both. PD-L1 was positive in 42.7% TURBT, 39.8% RC, and 27.3% LN specimens. Concordance was moderate (κ=0.52; P<0.001) between TURBT and RC, and fair between LN and TURBT (κ=0.31; P=0.048) or RC (κ=0.25; P=0.075). Comparison with the VENTANA PD-L1 (SP142) assay which had been performed previously on the same cohort showed moderate to substantial inter-assay agreement (κ=0.42-0.66). Although TC staining is not part of the SP142 scoring algorithm, discordant PD-L1 assay outcome could be attributed to SP263 TC≥25% staining in only 41% of cases. These results show that PD-L1 expression variability between matched specimens is higher than that between individual assays. Optimal specimen determination for PD-L1 testing needs to be addressed in future studies.

摘要

尿路上皮膀胱癌(UBC)患者不符合铂类化疗条件的,可以在 PD-L1 阳性病例中使用免疫检查点抑制剂(ICI)进行治疗。虽然不同的 PD-L1 检测方法之间存在一致性,但对于匹配的 UBC 样本中 PD-L1 表达的变异性知之甚少。我们比较了匹配的经尿道膀胱肿瘤切除术(TURBT)、根治性膀胱切除术(RC)和淋巴结转移(LN)的整块切片中的 PD-L1 表达。对 115 例患者进行了 VENTANA PD-L1(SP263)检测的免疫组化检测,如果≥25%的免疫细胞(IC)、≥25%的肿瘤细胞(TC)或两者均有表达,则为阳性。TURBT、RC 和 LN 标本中 PD-L1 阳性率分别为 42.7%、39.8%和 27.3%。TURBT 与 RC 之间的一致性为中度(κ=0.52;P<0.001),而 LN 与 TURBT(κ=0.31;P=0.048)或 RC(κ=0.25;P=0.075)之间的一致性为一般。与之前在同一队列中进行的 VENTANA PD-L1(SP142)检测进行比较显示,两种检测方法之间具有中度至高度的一致性(κ=0.42-0.66)。尽管 TC 染色不是 SP142 评分算法的一部分,但在只有 41%的情况下,SP263 TC≥25%染色可归因于 PD-L1 检测结果不一致。这些结果表明,匹配标本之间的 PD-L1 表达变异性高于单个检测方法之间的变异性。未来的研究需要确定 PD-L1 检测的最佳标本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/3b451779d12b/428_2021_3094_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/dd270747adb1/428_2021_3094_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/62fbacb9ed9e/428_2021_3094_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/3b451779d12b/428_2021_3094_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/dd270747adb1/428_2021_3094_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/62fbacb9ed9e/428_2021_3094_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42c7/8516767/3b451779d12b/428_2021_3094_Fig3_HTML.jpg

相似文献

1
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.PD-L1 在尿路上皮膀胱癌中的表达在不同标本类型之间的变化大于在伴随检测之间的变化。
Virchows Arch. 2021 Oct;479(4):705-713. doi: 10.1007/s00428-021-03094-6. Epub 2021 Apr 28.
2
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.PD-L1 表达在配对的尿路上皮膀胱癌标本中的一致性。
Histopathology. 2018 Dec;73(6):983-989. doi: 10.1111/his.13710. Epub 2018 Sep 25.
3
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.多中心分析性比较研究使用四种临床开发的免疫组织化学检测方法,检测尿路上皮膀胱癌肿瘤浸润免疫细胞和肿瘤细胞程序性死亡配体 1 的表达。
Virchows Arch. 2019 Nov;475(5):599-608. doi: 10.1007/s00428-019-02610-z. Epub 2019 Jul 2.
4
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.头颈部鳞状细胞癌、尿路上皮癌和乳腺癌中程序性死亡配体 1 评分的观察者间和观察者内一致性。
Histopathology. 2020 Jan;76(2):191-200. doi: 10.1111/his.13946. Epub 2019 Sep 9.
5
PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.PD-L1 在肌肉浸润性尿路上皮癌中的表达:SP142 和 SP263 检测方法的比较。
Indian J Pathol Microbiol. 2022 Oct-Dec;65(4):839-843. doi: 10.4103/ijpm.ijpm_1472_20.
6
RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.RUSSCO-RSP 免疫组织化学诊断检测法在膀胱癌 PD-L1 表达中的比较研究。
Virchows Arch. 2018 Dec;473(6):719-724. doi: 10.1007/s00428-018-2453-7. Epub 2018 Sep 13.
7
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.四种市售的、已验证的程序性死亡配体-1 检测方法在尿路上皮癌中的一致性。
Diagn Pathol. 2019 Sep 2;14(1):99. doi: 10.1186/s13000-019-0873-6.
8
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.PD-L1 免疫组织化学检测在膀胱尿路上皮癌和下咽鳞状细胞癌中的一致性。
Am J Surg Pathol. 2018 Aug;42(8):1059-1066. doi: 10.1097/PAS.0000000000001084.
9
Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.膀胱癌高级别尿路上皮癌的免疫基因表达谱:一项 NanoString 研究。
J Clin Pathol. 2021 Jan;74(1):53-57. doi: 10.1136/jclinpath-2020-206631. Epub 2020 May 29.
10
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?膀胱癌中 PD-L1 的表达:哪种评分算法在何种组织中?
Urol Oncol. 2021 Oct;39(10):734.e1-734.e10. doi: 10.1016/j.urolonc.2021.06.001. Epub 2021 Jul 11.

引用本文的文献

1
BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in bladder cancer progression.BAP1介导的泛素化抑制及CAS6/AXL信号激活在膀胱癌进展中的作用
Cytotechnology. 2025 Jun;77(3):95. doi: 10.1007/s10616-025-00757-z. Epub 2025 May 4.
2
[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].[德国关于程序性细胞死亡配体1(PD-L1)检测在肌层浸润性膀胱癌围手术期全身治疗中的专家共识]
Urologie. 2024 Oct;63(10):1019-1027. doi: 10.1007/s00120-024-02416-1. Epub 2024 Aug 26.
3
Evaluation of the Expression of Programmed Death-Ligand 1 and Its Role in Differentiating Low-Grade and High-Grade Urothelial Carcinoma.

本文引用的文献

1
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.四种市售的、已验证的程序性死亡配体-1 检测方法在尿路上皮癌中的一致性。
Diagn Pathol. 2019 Sep 2;14(1):99. doi: 10.1186/s13000-019-0873-6.
2
Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.原发性和转移性尿路上皮癌病变中高 PD-L1 表达的不一致性。
Urol Oncol. 2019 May;37(5):299.e19-299.e25. doi: 10.1016/j.urolonc.2019.01.002. Epub 2019 Jan 17.
3
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
程序性死亡配体1的表达评估及其在低级别和高级别尿路上皮癌鉴别中的作用
Cureus. 2024 Jun 17;16(6):e62567. doi: 10.7759/cureus.62567. eCollection 2024 Jun.
4
Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.将程序性死亡配体1(PD-L1)预后生物标志物整合到非肌层浸润性膀胱癌的临床实践中——关于最新进展和关键问题的综合综述
J Clin Med. 2024 Apr 10;13(8):2182. doi: 10.3390/jcm13082182.
5
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guérin (BCG) Therapy.高危非肌层浸润性膀胱癌中程序性死亡受体配体1(PD-L1)的表达受膀胱内卡介苗(BCG)治疗的影响。
Cancers (Basel). 2024 Mar 29;16(7):1356. doi: 10.3390/cancers16071356.
食品和药物管理局/EMA 批准的程序性死亡配体-1 检测在尿路上皮癌中的表现,重点是为阿替利珠单抗和帕博利珠单抗一线治疗进行的治疗分层。
Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.
4
PD-L1 Antibody Comparison in Urothelial Carcinoma.尿路上皮癌中PD-L1抗体的比较
Eur Urol. 2019 Mar;75(3):538-540. doi: 10.1016/j.eururo.2018.11.002. Epub 2018 Nov 27.
5
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.不同类型的泌尿生殖系统和头颈部癌、抗体克隆和组织类型的 PD-L1 免疫组化解读的可重复性。
Hum Pathol. 2018 Dec;82:131-139. doi: 10.1016/j.humpath.2018.07.024. Epub 2018 Aug 1.
6
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.PD-L1 表达在配对的尿路上皮膀胱癌标本中的一致性。
Histopathology. 2018 Dec;73(6):983-989. doi: 10.1111/his.13710. Epub 2018 Sep 25.
7
EMA restricts use of anti-PD-1 drugs for bladder cancer.欧洲药品管理局限制抗PD - 1药物用于膀胱癌治疗。
Lancet Oncol. 2018 Jul;19(7):e341. doi: 10.1016/S1470-2045(18)30433-9. Epub 2018 Jun 7.
8
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.PD-L1 免疫组织化学检测在膀胱尿路上皮癌和下咽鳞状细胞癌中的一致性。
Am J Surg Pathol. 2018 Aug;42(8):1059-1066. doi: 10.1097/PAS.0000000000001084.
9
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.原发性和转移性膀胱癌中 PD-L1 表达的一致性研究:四种常用抗体和 RNA 表达的比较。
Mod Pathol. 2018 Apr;31(4):623-632. doi: 10.1038/modpathol.2017.188. Epub 2017 Dec 22.
10
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.阿特珠单抗与化疗用于铂类治疗后局部晚期或转移性尿路上皮癌患者(IMvigor211):一项多中心、开放标签、III 期随机对照临床试验。
Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18.